Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. (May 2013)

• Record Type: Journal Article
• Authors: Lumley, Matthew; Perera, Divaka
• Is Part Of: Future cardiology. Volume 9:Number 3(2013)
• Page Start: 371
• Page End: 385
• Publication Date: 2013-05
• Subjects: acute coronary syndrome -- anticoagulant -- antiplatelet -- bleeding; Cardiology -- Research -- Periodicals; 616.12005
• DOI: 10.2217/fca.13.21
• Languages: English
• ISSNs: 1479-6678

Abstract

Multiple antiplatelet and anticoagulant therapies are available for the treatment of acute coronary syndromes. The combination of agents should be tailored to the individual patient carefully considering the balance between ischemic and bleeding risk, as well as the planned revascularization strategy. Despite multiple large-scale, rigorously designed and conducted randomized controlled trials, it can be difficult to select the correct pharmacotherapy for each patient and many unanswered questions remain, such as the safety and optimal doses of differing combinations of antiplatelet/anticoagulant therapy, as well as the timing and duration of therapies. In addition, the headline results of many trials report improved efficacy outcomes at the cost of increased bleeding risk; however, very few show a clear mortality benefit. It is therefore difficult to weigh up the risk–benefit profile of emerging therapies.